Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anifrolumab: SC formulation via AI
Anifrolumab: formulation via AI · 1 trial · 1 indication
To characterise the PK exposure of SC or IV anifrolumab.
| Arm | Type | Description |
|---|---|---|
| Part A: SC | EXPERIMENTAL | Participants will receive SC anifrolumab administered via AI. |
| Part A: IV | EXPERIMENTAL | Participants will receive IV anifrolumab infusion. |
| Part B | EXPERIMENTAL | Participants will receive SC anifrolumab administered via aPFS. |
| Name | Type | Description |
|---|---|---|
| Anifrolumab: SC formulation via AI | COMBINATION_PRODUCT | Anifrolumab will be administered subcutaneously via an AI. |
| Anifrolumab: IV formulation | COMBINATION_PRODUCT | Anifrolumab will be administered intravenously. |
| Anifrolumab: SC formulation via aPFS | COMBINATION_PRODUCT | Anifrolumab will be administered subcutaneously via an aPFS. |
Inclusion Criteria: * Participants who have a diagnosis of adult SLE according to the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 criteria for ≥ 24 weeks prior to signing the informed consent form (ICF). * "Clinical" Systemic Lupus Erythematosus Disease Acti...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
Anifrolumab is an investigational drug being studied for the treatment of Systemic Lupus Erythematosus (SLE). It is currently in Phase 1 clinical development, with a single active trial evaluating its pharmacokinetics, pharmacodynamics, and safety when administered subcutaneously or intravenously. The drug is not yet approved and remains under investigation.
Anifrolumab is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting a Phase 1 clinical trial to evaluate the drug's pharmacokinetics, pharmacodynamics, and safety in patients with Systemic Lupus Erythematosus.
Anifrolumab is in Phase 1 clinical development. The ongoing trial, NCT07688980, is designed to characterize the drug's pharmacokinetics, pharmacodynamics, and safety when administered subcutaneously or intravenously. This is an early-stage study, and the drug remains investigational, not yet approved for any use.
Anifrolumab is currently in one active clinical trial, identified as NCT07688980. This Phase 1 study is titled 'Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)' and is enrolling 92 participants with Systemic Lupus Erythematosus. The trial is not yet recruiting.
Yes, Anifrolumab is also known as Anifrolumab SC formulation via AI. This alternative name refers to the subcutaneous formulation of the drug, which is being evaluated in clinical trials alongside the intravenous route of administration. Both names refer to the same investigational drug developed by AstraZeneca for Systemic Lupus Erythematosus.